DexCom is trading 6.1% up at $79.07 after reporting better-than-expected second quarter results and raising its full-year 2026 outlook.
- Revenue grew 13% year-over-year to $1.308 billion, supported by sharp margin expansion and increased profitability guidance.
- Management highlighted a strategic push into the non-insulin Type 2 diabetes market amid a broadly positive backdrop for growth stocks.